Subtype-specific therapies: FLT3 inhibitors for ZNF384-rearranged B-ALL and HDAC inhibitors for MEF2D-rearranged disease represent emerging avenues. The gene discussed is HDAC9; the disease is acute lymphoblastic leukemia.